Health
Beam Therapeutics CEO on CRISPR’s future, sickle cell research: The Endpoints Slack interview - Endpoints News
Even with last year's landmark approvals for genetic medicines in sickle cell disease, John Evans is convinced his startup can push the field further. Beam Therapeutics started 2024 by announcing it had dosed the first sickle cell patient with its ba
By: Endpoints News
- Feb 06 2024
- 0
- 0 Views
Even with last year’s landÂmark apÂprovals for geÂnetÂic medÂiÂcines in sickÂle cell disÂease, John Evans is conÂvinced his startÂup can push the field furÂther.
Beam TherÂaÂpeuÂtics startÂed 2024 b… [+647 chars]